R&D News | pharmaphorum

News

Boehringer bets up to $500m on Sitryx immunology programme

Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.

News

Head to head figurine fights, red and blue

Lilly says orforglipron tops Novo pill in diabetes trial

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.

News

Asahi Kasei buys antiviral firm Aicuris for €780m

Asahi Kasei has agreed to buy Germany's Aicuris for around $920m, adding an antiviral drug it hopes will help drive its 2030 pharma sales to $1.9bn.

News

Changes at the top of Sarepta, Alkermes, as CEOs depart

Two long-serving pharma CEOs have announced their departures, as Sarepta's Doug Ingram and Alkermes' Richard Pops announce their retirement.

News

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.

News

GSK grows pipeline with 35Pharma takeover, Frontier deal

GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.

Boehringer bets up to $500m on Sitryx immunology programme

Lilly says orforglipron tops Novo pill in diabetes trial

Asahi Kasei buys antiviral firm Aicuris for €780m

Changes at the top of Sarepta, Alkermes, as CEOs depart

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

GSK grows pipeline with 35Pharma takeover, Frontier deal

UK offers meningitis jab to young people after outbreak

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks